Meyahealth
HomeGeneticsGeneTFAP2A gene
Back to Gene
TFAP2A gene
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Gene

TFAP2A gene

The TFAP2A gene provides instructions for making a protein that regulates gene activity during early embryonic development, particularly in the formation of the head and neck.

Normal Function

The TFAP2A gene provides instructions for making a protein called transcription factor AP-2 alpha (AP-2α). As a transcription factor, this protein attaches (binds) to specific regions of DNA to help control the activity of particular genes. It belongs to a group of related proteins called AP-2 transcription factors, which regulate genes involved in cell division and the self-destruction (apoptosis) of cells that are no longer needed.

Transcription factor AP-2α is active during development before birth, specifically within the neural crest—a group of cells in the early embryo that give rise to many tissues and organs. It is particularly important for the development of the branchial arches, which form the bones and other tissues of the head and neck.

Health Conditions Related to Genetic Changes

Branchio-oculo-facial syndrome

Mutations in the TFAP2A gene cause branchio-oculo-facial syndrome. This condition is characterized by skin anomalies on the neck, malformations of the eyes and ears, and distinctive facial features. Most mutations associated with this syndrome change single amino acids in the AP-2α protein, typically in the region responsible for DNA binding. This likely impairs the protein's ability to control gene activity, disrupting the development of structures derived from the branchial arches.

Anophthalmia/Microphthalmia

The TFAP2A gene is associated with anophthalmia/microphthalmia.

Coloboma

The TFAP2A gene is associated with coloboma.

Other Names for This Gene

  • activating enhancer-binding protein 2-alpha
  • activator protein 2
  • AP-2
  • AP-2 transcription factor
  • AP-2alpha
  • AP2-alpha
  • AP2A_HUMAN
  • AP2TF
  • BOFS
  • TFAP2
  • transcription factor AP-2 alpha (activating enhancer binding protein 2 alpha)
  • transcription factor AP-2-alpha

Frequently Asked Questions

The condition is inherited in an autosomal dominant pattern. If a parent has the condition, there is a 50 percent chance of passing the mutation to each child. However, many cases arise from new (de novo) mutations with no family history. If a child is diagnosed with a de novo mutation, the risk for future siblings is generally low, but parental testing may be recommended to rule out germline mosaicism, where a parent carries the mutation in a small number of cells.
Doctors look for a specific triad of features: skin anomalies on the neck (such as branchial clefts or fistulas), eye abnormalities (like microphthalmia or colobomas), and distinctive facial features (including a broad nasal bridge, low-set ears, and a wide mouth). Because these signs can vary in severity, a clinical evaluation by a geneticist or specialist is necessary to correlate these findings with potential TFAP2A gene mutations.
No, branchio-oculo-facial syndrome does not typically affect cognitive development or intelligence. Individuals with this condition usually have normal intellectual abilities. The primary challenges are related to the physical manifestations, such as managing eye health, hearing issues due to ear malformations, and potential complications from neck skin anomalies, but these do not impact brain function or learning capacity.
Confirmation involves genetic testing to identify pathogenic variants in the TFAP2A gene. This is usually performed through a blood or saliva sample. Since most associated mutations are point mutations that alter single amino acids in the DNA-binding region of the protein, targeted sequencing or whole-exome/genome sequencing may be used. A positive genetic test confirms the diagnosis and helps rule out other syndromes with overlapping features.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

Meyahealth

Ⓒ 2026. All rights reserved by MEYA

About UsTerms & PolicyFAQ